Back to top
more

KemPharm, Inc. (KMPH)

(Delayed Data from NSDQ)

$1.37 USD

1.37
193,792

+0.06 (4.58%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.37 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Zevra Therapeutics, Inc. [KMPH]

Reports for Purchase

Showing records 1 - 20 ( 116 total )

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

02/27/2023

Daily Note

Pages: 8

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

02/24/2023

Company Report

Pages: 6

Two Posters Presented at WORLDSymposium for Arimoclomol in NPC

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

01/11/2023

Company Report

Pages: 6

Management Changes Reflect Maturing Company, Expecting Eventful 2023

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

01/11/2023

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

12/22/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

12/21/2022

Company Report

Pages: 5

Starts Phase 2 Trial KP1077 Trial in Idiopathic Hypersomnia

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

12/21/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

11/14/2022

Company Report

Pages: 7

Arimoclomol -Delay- Not Material; It?s Still All Upside For Us; Azstarys Rx Ramping; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

11/10/2022

Company Report

Pages: 6

3Q22: Several Relatively Near-Term Events, Well-Funded & Capital Efficient

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

11/10/2022

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

09/29/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

09/28/2022

Company Report

Pages: 5

SDX Delivers Positive Phase 1 Single- Dose Cardiovascular Safety Results

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

08/17/2022

Company Report

Pages: 8

Azstarys Rx Ramping; Arimoclomol and KP1077 Clarity Coming; Tweak PT to $10 on Lower Azstarys, But Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

08/15/2022

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

08/12/2022

Company Report

Pages: 5

2Q22: Several Relatively Near-Term Events, Well-Funded & Capital Efficient

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

06/02/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

06/02/2022

Company Report

Pages: 6

Published Results Show Highly Favorable Safety and Abuse Profile of SDX

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

05/18/2022

Company Report

Pages: 9

Arimoclomol Ultra-Rare CNS Play Truly Looks Like a Free Call Option; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

05/16/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

05/16/2022

Company Report

Pages: 6

1Q22: Acquires Arimoclomol from Orphazyme, SDX in Phase 1, Well Funded

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party
// eof